Locoregional treatments of hepatocellular carcinoma (HCC) have evolved over the past 20 years. Interventional radiologists have developed an important role in the palliative and curative treatment of the disease. This review summarizes commonly used interventional radiological treatment protocols to assist practitioners in understanding the techniques used to treat HCC.
Methods
Various searches were performed to evaluate recent publications regarding systemic treatments of HCC as well as transplant/surgery, chemoembolization, yttrium-90 radioembolization, percutaneous radiofrequency ablation (RFA), cryoablation, and percutaneous ethanol injection (PEI).
Results
No standard for chemoembolization was found. Two studies evaluating survival with chemoembolization vs medical therapy found benefits with the former. PEI offers favorable outcomes in small HCC but has increased recurrence and decreased long-term survival compared with RFA. Local recurrence, response rates, and mortality from RFA rival surgical resection in HCC < 3 cm. Cryoablation appears to be effective, and yttrium-90 radioembolization is an additional tool.
Conclusions
Chemoembolization improves survival and offers improved tumor response compared to systemic treatment. More studies are needed to standardize chemoembolization preparations and techniques. RFA provides better results than PEI but has not been compared with cryoablation. Radioembolization appears to be as effective as chemoembolization, but the preprocedure evaluation and costs may limit its use.
References
1.
El-SeragH.B., MasonA.C., KeyC.. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.Hepatology.2001; 33(1): 62–65.
2.
AltekruseS.F., McGlynnK.A., ReichmanM.E.. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.J Clin Oncol.2009; 27(9): 1485–1491.
3.
KondoF.. Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application: hepatocellular carcinoma.Hepatol Int.2009; 3(1): 283–293.
4.
El-SeragH.B., RudolphK.L.. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.Gastroenterology.2007; 132(7): 2557–2576.
5.
HayashiM., MatsuiO., UedaK.. Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium.AJR Am J Roentgenol.1999; 172(4): 969–976.
6.
TakayasuK., MuramatsuY., FurukawaH.. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation.Radiology.1995; 194(1): 101–105.
7.
HayashiM., MatsuiO., UedaK.. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material.Radiology.2002; 225(1): 143–149.
8.
PawlikT.M., DelmanK.A., VautheyJ.N.. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma.Liver Transpl.2005; 11(9): 1086–1092.
9.
JonasS., BechsteinW.O., SteinmüllerT.. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.Hepatology.2001; 33(5): 1080–1086.
BurroughsA., HochhauserD., MeyerT.. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum.Lancet Oncol.2004; 5(7): 409–418.
12.
FussM., SalterB.J., HermanT.S.. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and imageguided radiation therapy.Gastroenterology.2004; 127(5 suppl 1): S206–S217.
13.
OttoG., HeuschenU., HofmannW.J.. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis.Ann Surg.1998; 227(3): 424–432.
14.
PoonR.T., FanS.T., LoC.M.. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation.Ann Surg.2002; 235(3): 373–382.
15.
FiguerasJ., JaurrietaE., VallsC.. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.Hepatology.1997; 25(6): 1485–1489.
16.
LlovetJ.M., FusterJ., BruixJ.. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Hepatology.1999; 30(6): 1434–1440.
17.
KamathP.S., WiesnerR.H., MalinchocM.. A model to predict survival in patients with end-stage liver disease.Hepatology.2001; 33(2): 464–470.
18.
WiesnerR.H., McDiarmidS.V., KamathP.S.. MELD and PELD: application of survival models to liver allocation.Liver Transpl.2001; 7(7): 567–580.
19.
KremersW.K., van IJperenM., KimW.R.. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients.Hepatology.2004; 39(3): 764–769.
20.
BrownD.B., FundakowskiC.E., Lisker-MelmanM.. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma.J Vasc Interv Radiol.2004; 15(11): 1209–1218.
21.
SchwartzM.. Liver transplantation for hepatocellular carcinoma.Gastroenterology.2004; 127(suppl 1): 268–276.
22.
CilloU., BassanelloM., VitaleA.. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available?J Hepatol.2004; 40(1): 124–131.
23.
GeorgiadesC.S., LiapiE., FrangakisC.. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization.J Vasc Interv Radiol.2006; 17(10): 1619–1624.
24.
MarreroJ.A., FontanaR.J., BarratA.. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort.Hepatology.2005; 41(4): 707–716.
25.
YaoF.Y., FerrellL., BassN.M.. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria.Liver Transpl.2002; 8(9): 765–774.
26.
ChouF.I., FangK.C., ChungC.. Lipiodol uptake and retention by human hepatoma cells.Nucl Med Biol.1995; 22(3): 379–386.
27.
KanZ., McCuskeyP.A., WrightK.C.. Role of Kupffer cells in iodized oil embolization.Invest Radiol.1994; 29(11): 990–993.
28.
KonnoT.. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium.Cancer.1990; 66(9): 1897–1903.
29.
SasakiY., ImaokaS., KasugaiH.. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge.Cancer.1987; 60(6): 1194–1203.
30.
OlwenyC.L., ToyaT., Katongole-MbiddeE.. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication.Cancer.1975; 36(4): 1250–1257.
31.
OlwenyC.L., Katongole-MbiddeE., BahendekaS.. Further experience in treating patients with hepatocellular carcinoma in Uganda.Cancer.1980; 46(12): 2717–2722.
32.
LaiC.L., WuP.C., ChanG.C.. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.Cancer.1988; 62(3): 479–483.
33.
LeungT.W., TangA.M., ZeeB.. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.Cancer.2002; 94(2): 421–427.
34.
LeungT.W., PattY.Z., LauW.Y.. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.Clin Cancer Res.1999; 5(7): 1676–1681.
35.
SolomonB., SoulenM.C., BaumR.A.. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population.J Vasc Interv Radiol.1999; 10(6): 793–798.
36.
VarelaM., RealM.I., BurrelM.. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.J Hepatol.2007; 46(3): 474–481.
37.
BrownD.B., CardellaJ.F., SacksD.. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy.J Vasc Interv Radiol.2009; 20(7 suppl): S219–S226, S226.e1-10.
38.
GeorgiadesC.S., HongK., D'AngeloM.. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.J Vasc Interv Radiol.2005; 16(12): 1653–1659.
39.
SakamotoI., AsoN., NagaokiK.. Complications associated with transcatheter arterial embolization for hepatic tumors.Radiographics.1998; 18(3): 605–619.
40.
TakayasuK., AriiS., IkaiI.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.Gastroenterology.2006; 131(2): 461–469.
41.
BrownD.B., GeschwindJ.F., SoulenM.C.. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.J Vasc Interv Radiol.2009; 20(7 Suppl): S317–S323.
42.
KimW., ClarkT.W., BaumR.A.. Risk factors for liver abscess formation after hepatic chemoembolization.J Vasc Interv Radiol.2001; 12(8): 965–968.
43.
LlovetJ.M., RealM.I., MontañaX.. Arterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet.2002; 359(9319): 1734–1739.
44.
LoC.M., NganH., TsoW.K.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology.2002; 35(5): 1164–1171.
45.
LlovetJ.M., BruixJ.. Systematic review of randomized trials for unre-sectable hepatocellular carcinoma: chemoembolization improves survival.Hepatology.2003; 37(2): 429–442.
46.
CammàC., SchepisF., OrlandoA.. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.Radiology.2002; 224(1): 47–54.
47.
MabedM., EsmaeelM., El-KhodaryT.. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.Eur J Cancer Care (Engl).2009; 18(5): 492–499.
48.
LammerJ., MalagariK., VoglT.. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.Cardiovasc Intervent Radiol.2010; 33(1): 41–52.
49.
MalagariK., PomoniM., KelekisA.. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.Cardiovasc Intervent Radiol.2009 Nov 24. Epub ahead of print.
50.
SalemR., LewandowskiR.J., AtassiB.. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.J Vasc Interv Radiol.2005; 16(12): 1627–1639.
RiazA., LewandowskiR., KulikL.. Complications following radioembolization with yttrium-90 microspheres: a comprohensive literature review.J Vasc Interv Radiol.2009; 20(9): 1121–1130.
53.
SalemR., LewandowskiR., RobertsC.. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.J Vasc Interv Radiol.2004; 15(4): 335–345.
54.
SalemR., LewandowskiR.J., MulcahyM.F.. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.Gastroenterology.2010; 138(1): 52–64.
55.
KoobyD.A., EgnatashviliV., SrinivasanS.. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.J Vasc Interv Radiol.2010; 21(2): 224–230.
56.
IshiiH., OkadaS., NoseH.. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection.Cancer.1996; 77(9): 1792–1796.
57.
LencioniR.A., AllgaierH.P., CioniD.. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection.Radiology.2003; 228(1): 235–240.
58.
ShiinaS., TerataniT., ObiS.. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.Gastroenterology.2005; 129(1): 122–130.
59.
LinS.M., LinC.J., LinC.C.. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less.Gut.2005; 54(8): 1151–1156.
60.
OrlandoA., LeandroG., OlivoM.. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.Am J Gastroenterol.2009; 104(2): 514–524.
61.
PermpongkosolS., NicolT.L., LinkR.E.. Differences in ablation size in porcine kidney, liver, and lung after cryoablation using the same ablation protocol.AJR Am J Roentgenol.2007; 188(4): 1028–1032.
62.
GageA.A., BaustJ.. Mechanisms of tissue injury in cryosurgery.Cryo-biology.1998; 37(3): 171–186.
63.
ChuaK.J., ChouS.K., HoJ.C.. An analytical study on the thermal effects of cryosurgery on selective cell destruction.J Biomech.2007; 40(1): 100–116.
64.
PermpongkosolS., NicolT.L., KhuranaH.. Thermal maps around two adjacent cryoprobes creating overlapping ablations in porcine liver, lung, and kidney.J Vasc Interv Radiol.2007; 18(2): 283–287.
65.
BilchikA.J., WoodT.F., AllegraD.. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm.Arch Surg.2000; 135(6): 657–662; discussion 662-664.
66.
AllafM.E., VarkarakisI.M., BhayaniS.B.. Pain control requirements for percutaneous ablation of renal tumors: cryoablation versus radiofrequency ablation — initial observations.Radiology.2005; 237(1): 366–370.
67.
SungG.T., GillI.S., HsuT.H.. Effect of intentional cryo-injury to the renal collecting system.J Urol.2003; 170(2 Pt 1): 619–622.
AdamR., HagopianE.J., LinharesM.. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies.Arch Surg.2002; 137(12): 1332–1339; discussion 1340.
70.
PearsonA.S., IzzoF., FlemingR.Y.. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies.Am J Surg.1999; 178(6): 592–599.
71.
SeifertJ.K., MorrisD.L.. World survey on the complications of hepatic and prostate cryotherapy.World J Surg.1999; 23(2): 109–113; discussion 113-114.
72.
KerkarS., CarlinA.M., SohnR.L.. Long-term follow up and prognostic factors for cryotherapy of malignant liver tumors.Surgery.2004; 136(4): 770–779.
LuD.S., RamanS.S., LimanondP.. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors.J Vasc Interv Radiol.2003; 14(10): 1267–1274.
77.
ChangI., MikityanskyI., Wray-CahenD.. Effects of perfusion on radiofrequency ablation in swine kidneys.Radiology.2004; 231(2): 500–505.
78.
PompiliM., MiranteV.G., RondinaraG.. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence.Liver Transpl.2005; 11(9): 1117–1126.
79.
MazzaferroV., BattistonC., PerroneS.. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study.Ann Surg.2004; 240(5): 900–909.
80.
LuD.S., YuN.C., RamanS.S.. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.Radiology.2005; 234(3): 954–960.
81.
McGhanaJ.P., DoddGD3rd. Radiofrequency ablation of the liver: current status.AJR Am J Roentgenol.2001; 176(1): 3–16.
82.
ChenM.S., LiJ.Q., ZhengY.. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma.Ann Surg.2006; 243(3): 321–328.
83.
GervaisD.A., GoldbergS.N., BrownD.B.. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors.J Vasc Interv Radiol.2009; 20(7 Suppl): S342–S347.
84.
KoffronA.J., AuffenbergG., KungR.. Evaluation of 300 minimally invasive liver resections at a single institution: less is more.Ann Surg.2007; 246(3): 385–392; discussion 392-394.
85.
LlovetJ.M., VilanaR., BrúC.. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.Hepatology.2001; 33(5): 1124–1129.
86.
JaskolkaJ.D., AschM.R., KachuraJ.R.. Needle tract seeding after radiofrequency ablation of hepatic tumors.J Vasc Interv Radiol.2005; 16(4): 485–491.
87.
AhmedM., LiuZ., LukyanovA.N.. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals.Radiology.2005; 235(2): 469–477.
88.
LencioniR., CrocettiL., PetruzziP.. Doxorubicin-eluting beadenhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study.J Hepatol.2008; 49(2): 217–222.
89.
YamakadoK., NakatsukaA., OhmoriS.. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology.J Vasc Interv Radiol.2002; 13(12): 1225–1232.
90.
LiaoG.S., YuC.Y., ShihM.L.. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma.Eur J Surg Oncol.2008; 34(1): 61–66.
91.
AkamatsuM., YoshidaH., ObiS.. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.Liver Int.2004; 24(6): 625–629.
92.
YangW., ChenM.H., WangM.Q.. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment.Hepatol Res.2009; 39(3): 231–240.
93.
VeltriA., MorettoP., DoriguzziA.. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).Eur Radiol.2006; 16(3): 661–669.
94.
ZhangY.J., LiangH.H., ChenM.S.. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial.Radiology.2007; 244(2): 599–607.
